November 21st 2024
Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Disease-Free, Overall Survival Lower in Patients With CRC Treated With PE, CRS/HIPEC
March 14th 2024Patients with stage IV colorectal cancer (CRC) had lower overall and disease-free survival if they had a pelvic exenteration (PE) or cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
Read More
Quality of Life, Severity Scales Correlated in Patients With Psoriasis Worldwide
March 13th 2024Study findings show that scores on the Psoriasis Area and Severity Index and the Dermatology Quality of Life Index are correlated in patients with psoriasis across several continents, but factors affecting each of these scores are different across countries.
Read More
SABR Likely Safe, Effective for Patients Who Have NSCLC, ILD
March 12th 2024In this study, the 42-patient population was enrolled from 5 sites in Canada and 1 site in Scotland, and data were gathered from March 7, 2019, to January 12, 2022; all had interstitial lung disease (ILD) and early-stage non–small cell lung cancer (NSCLC).
Read More
FDA Issues CRL for Glatiramer Acetate Depot for Relapsing Forms of MS
March 11th 2024The FDA has declined to approve glatiramer acetate (GA) depot in the treatment of relapsing types of multiple sclerosis (MS), issuing a complete response letter (CRL) for the long-acting, injectable form of GA.
Read More
From Stigma to Solutions: MBGH Panel Explores Mental Health Paradigm Shift in the Workplace
March 8th 2024The critical issue of mental health in the workplace was discussed by experts in the field at the recent Midwest Business Group on Health (MBGH) Mental Health Forum, shedding light on the growing concern surrounding alcohol use disorder and the pressing need for innovative therapies.
Read More
FDA Approves Semaglutide to Prevent Heart Events in Patients With CVD and Excess Weight
March 8th 2024The FDA added another indication for semaglutide (Wegovy), expanding its use to reduce the risk of cardiovascular death, heart attack, or stroke in adults who have cardiovascular disease (CVD) and overweight or obesity.
Read More
Improving Glycemic Control in Diabetes Through Virtual Interdisciplinary Rounds
Patients with diabetes whose providers received advice from remote, virtual interdisciplinary rounds had a greater 1-year reduction in hemoglobin A1c than comparable patients.
Read More
Inappropriate Wrist MRI: Did Guidelines Have an Impact?
This article analyzes the use of MRI in a national sample of patients with wrist pain before and after consensus guideline publication.
Read More
President Biden will preview his plan to more than double the size of Medicare’s new drug price negotiation program in the upcoming State of the Union address; Mexicans and Central Americans were most affected by the pandemic in terms of all-cause mortality; two Alabama fertility clinics said they expect to resume in vitro fertilization (IVF) services after a bill was passed to protect doctors.
Read More
Case Report Warns of Pneumothorax Risk in Duchenne Muscular Dystrophy
March 6th 2024The authors of this report stress the importance of awareness of COVID-19–related complications in young patients who have Duchenne muscular dystrophy, paying particular attention to a potential higher risk of respiratory infections in these patients.
Read More
Promise of AI in MS Research and Treatment Showcased at ACTRIMS 2024
March 3rd 2024The poster session at the Americas Committee for Research and Treatment in Multiple Sclerosis (ACTRIMS) Forum 2024 dedicated a section to emerging developments in the use of artificial intelligence (AI) in research and treatment approaches in multiple sclerosis (MS).
Read More